Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer
- Authors
- Lee, Suk-Young; Choi, Yun Ji; Seo, Jae Hong; Lee, Sung Yong; Kim, Jung Sun; Kang, Eun Joo
- Issue Date
- 11월-2019
- Publisher
- AME PUBL CO
- Keywords
- Advanced lung cancer; obstructive lung disease; lung function; prognostic indicator
- Citation
- JOURNAL OF THORACIC DISEASE, v.11, no.11, pp.4562 - 4572
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THORACIC DISEASE
- Volume
- 11
- Number
- 11
- Start Page
- 4562
- End Page
- 4572
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/62043
- DOI
- 10.21037/jtd.2019.10.77
- ISSN
- 2072-1439
- Abstract
- Background: The impacts of pulmonary function in patients with metastatic non-small cell lung cancer (NSCLC) and extended disease stage small cell lung cancer (SCLC-ED) treated with palliative chemotherapy remain to still be determined. Methods: Results of spirometry performed in 449 patients with either stage IV NSCLC (n=313) or SCLC-ED (n=136) at diagnosis were reviewed retrospectively. Overall survival (OS) was estimated using the Kaplan-Meier method and compared via a log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model. Results: The presence of chronic obstructive pulmonary disease (COPD) was not a risk factor for OS in either NSCLC or SCLC. However, NSCLC patients with COPD with a forced expiratory volume in one second (FEV1) value of less than 80% predicted were associated with a worse OS in both univariate and multivariate analyses [hazard ratio (HR): 1.43; 95% confidence interval (CI): 1.04-1.97; P=0.03]. Intriguingly, only the OS of NSCLC patients treated with chemotherapeutic agents was affected by the airflow limitation FEV1 value of less than 80% predicted (P=0.02). Patients with an FEV1 value of less than 80% predicted treated with targeted agents were not associated with OS (P=0.24). On the other hand, NSCLC patients with COPD were significantly linked to the occurrence of pulmonary complications during palliative therapy (P=0.01) but not associated with death resulting from pulmonary complications (P=0.22). Conclusions: Careful attention is required when chemotherapeutic agents are administered to patients with metastatic NSCLC with accompanying COPD with a FEV1 value of less than 80% predicted.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.